Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹685.95
Previous CloseN/A
Volume14.19K
Average Volume (3M)1.03K
Market Cap
₹36.18B
Enterprise Value₹22.74K
Total Cash (Recent Filing)₹2.99B
Total Debt (Recent Filing)₹5.00B
Price to Earnings (P/E)14.3
Beta1.34
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)35.91
Shares Outstanding70,405,754
10 Day Avg. Volume1,013
30 Day Avg. Volume1,033
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageSustained low leverage and growing equity provide durable financial flexibility and resilience. This reduces refinancing and solvency risk during industry cycles, supports capacity to fund organic investment or absorb shocks, and preserves optionality for partnerships or acquisitions.
Diversified Pharma Business Model And Manufacturing CapabilityA multi‑channel model (domestic brands, exports, and API sales) and in‑house manufacturing plus regulatory compliance create structural advantages. Diversification across products and geographies smooths revenue volatility and enables market entry and long‑term contract opportunities.
Historical Revenue Expansion And Recent Profitability RecoveryPrior multi‑year top‑line growth and a return to net profitability indicate underlying market demand and improved cost or mix outcomes. Sustained revenue growth combined with recent margin recovery supports reinvestment capacity and the prospect of durable earnings re‑acceleration if trends persist.
Bears Say
Weak Cash Generation And Negative Free Cash FlowPersistent negative operating and free cash flow is a material structural weakness: it constrains self‑funding of capex, R&D and working capital, increases dependence on external financing, and raises execution risk if funding conditions tighten or margins slip.
Volatile Profitability And Thin Operating MarginsEarnings volatility and a very thin operating margin limit the firm's ability to absorb cost inflation or pricing pressure. Such narrow operating buffers make long‑term margin sustainability uncertain and heighten sensitivity of reported profits to small demand or cost swings.
Recent Revenue Dip And Uneven Returns On EquityA recent top‑line decline and historically weak ROE reduce internal capital generation and constrain long‑term growth financing. Modest returns when profitable suggest the balance sheet isn't being consistently translated into high economic returns, limiting shareholder value durability.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹685.95 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹36.18B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is Aug 11, 2026 which is in 7 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on May 22, 2026. The company reported ₹1.55 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.55.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of N/A. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹1.55 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.799%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Windlas Biotech Ltd.
―